MedPage Today on MSN14h
MIND Diet and Cognitive Decline; Gene Therapy for Parkinson's; Curbing MS Fatigue
A high dose of the investigational gene therapy AAV-GAD, which delivers the glutamic acid decarboxylase ( GAD) gene to the ...
MeiraGTx’s Parkinson’s gene therapy shows promise in Phase I/II study
The AAV-GAD bridging study met the primary endpoint of safety and tolerability, and showed early promise in Parkinson’s ...
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx Holdings ’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD ...
Yahoo Finance6d
MGTX Stock Up on Upbeat Efficacy Data From Parkinson's Disease Study
MeiraGTx Holdings’ MGTX clinical bridging study of its gene therapy candidate, AAV-GAD, for treating Parkinson’s disease (PD) met its primary study objective of safety and tolerability.
pharmaphorum1d
MeiraGTx plans to take Parkinson's gene therapy into phase 3
Shares in the Anglo-US biotech rose sharply after the announcement, which came off the back of new data showing that the AAV-GAD gene therapy met targets for safety and efficacy in the MGT-GAD-025 ...
MeiraGTx Holdings: Promising Growth Potential with Strategic Manufacturing and Positive Clinical Results
Alec Stranahan, an analyst from Bank of America Securities, maintained the Buy rating on Meiragtx Holdings (MGTX – Research Report). The ...
Nasdaq6d
MeiraGTx (MGTX) Surges 14.9%: Is This an Indication of Further Gains?
The stock price rally was observed after the company reported positive topline data from its clinical bridging study of AAV-GAD for treating Parkinson’s disease (PD). Per the data readout ...